 |
|
Group A Streptococcal Vaccines
Michael E. Pichichero, MD
JAMA. 2004;292:738-739.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In this issue of JAMA, Kotloff and colleagues1 report on the safety and immunogenicity of a recombinant multivalent M protein group A streptococcal (GAS) vaccine evaluated in 28 healthy adult volunteers. This preliminary report is a positive step in a long journey ahead to develop a GAS vaccine.
Numerous attempts to immunize humans against GAS infections date back to the 1930s, when dead GAS intravenously administered to children who had rheumatic fever reportedly decreased recurrence rates.2-3 There was no evidence that these immunizations caused or reactivated rheumatic fever. In the 1940s, heat-killed and ultraviolet-killed GAS was administered subcutaneously, repetitively, and in high inocula to hundreds of military recruits with evidence of toxicity but not efficacy.4
The role of M type-specific antibodies in human immunity was first evaluated in the early 1950s. Infection with homologous M types of GAS occurred 6 times as frequently among adults . . . [Full Text of this Article]
Author Affiliation: Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY.
RELATED ARTICLE
Safety and Immunogenicity of a Recombinant Multivalent Group A Streptococcal Vaccine in Healthy Adults: Phase 1 Trial
Karen L. Kotloff, Mary Corretti, Kathleen Palmer, James D. Campbell, Mark A. Reddish, Mary C. Hu, Steven S. Wasserman, and James B. Dale
JAMA. 2004;292(6):709-715.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
International Quality Assurance Study for Characterization of Streptococcus pyogenes
Neal et al.
J. Clin. Microbiol. 2007;45:1175-1179.
ABSTRACT
| FULL TEXT
|
